The British Society for Immunology and NanoString, in collaboration with Illumina, will award two grants to enable the discovery of spatial biomarkers using the latest Digital Spatial Profiling chemistry. One grant will be awarded to the most impactful proposals in COVID-19 host response research, and one grant will be awarded to the most impactful proposal for Immunology research.
Grant applications are open to all immunologists across Europe.
AWARD 1: COVID-19 Research
The NanoString GeoMx® COVID-19 Immune Response Atlas, for use with the GeoMx® Digital Spatial Profiler (DSP), blends high-plex and spatial analysis in a single experiment. The GeoMx COVID-19 Immune Response Atlas, a ~1,850-plex RNA assay, enables spatial studies of the SARS-CoV-2 virus and host response. RNA targets include COVID-19 receptors and proteases, pulmonary alveolar type I and II markers, lung biology markers, viral response markers, and SARS-CoV-2 probes. RNA targets are profiled simultaneously using the GeoMx DSP and an Illumina next-generation sequencer (NGS) for readout. The read out will be performed with the Illumina NextSeq™ 2000 Sequencing System located at NanoString’s premises
AWARD 2: Immunology Research:
The GeoMx® Whole Transcriptome Atlas (WTA) is designed for comprehensive profiling of spatial biology. Profile the RNA expression over 18,000 genes in human and over 21,000 genes in mouse with spatial resolution in any region of interest from a single tissue section using the GeoMx Digital Spatial Profiler. The read out will be performed with the Illumina NextSeq™ 2000 Sequencing System located at NanoString’s premises.
Win either a free GeoMx COVID-19 Immune Response Atlas project or a free GeoMx® Whole Transcriptome Atlas (WTA). Both awards include NGS readout on Illumina's new NextSeq™ 2000 Sequencing System.
- Data analysis service is provided by expert NanoString scientists to help you quickly gain the most insight from your data.
- Utilizing the Illumina NextSeq™ 2000 Sequencing System and associated reagent kit for the NGS readout will allow you to unveil critical markers and drive your project to the next level.
Applications now closed.
Terms and Conditions
Publication of Project Results:
All grant submissions are confidential to the individual submitter and will not be published or distributed, however NanoString may share them with their own staff and distributors who will not disclose to third party.
Illumina will support the grant advertising efforts and will provide the reagent kit for the NGS readout. Illumina will not receive any information on the projects submitted or the submissions themselves. Nanostring will provide Illumina with the names and email addresses of all applicants as well as their affiliated institution.
The winners will be selected by a panel of judges that includes BSI Board members, as well as representation from NanoString.
Upon project completion, the grant winners agree to participate in at least one of the following activities relating to the specific project, with specific details of the applicable activity to be mutually agreed upon in good faith by NanoString, Illumina and the winner: webinar, case study, blog post, or poster presentation. The winner agrees that NanoString and Illumina shall have the right to publicly announce the winner’s name and research title and use anonymized data from the winner's projects in application notes including in marketing materials and seminars- no public display of data will happen without previous consent from the winner.
Eligibility and Requirements:
Applicants must be actively enrolled or employed at a research institution in a capacity in which they perform life science research and have the ability to ship and analyze samples within 45 days of award notification.
Members of the immediate families of the BSI, Illumina and NanoString employees and directors, and/or persons living in the same household as such persons, are ineligible to participate in this grant program.
Applicants must not be government employees or a Health Care Professionals. Employees of government institutions and Health Care Professionals should not be eligible to participate in the program. Health Care Professional is defined as physicians, nurses, physician assistants, pharmacists, and any other medical professionals, including without limitation, medical students, laboratory directors, genetic counselors, and formulary committee members.
The Covid Research grant winner will provide 2 samples to NanoString, with up to 24 Regions of Interest (ROI) per sample to be mutually agreed upon, to be used with the GeoMx® COVID-19 Immune Response Atlas and Illumina NGS appropriate reagents for use with the Illumina NextSeq™ 2000 Sequencing System.
The Immunology grant winner will provide 2 samples to NanoString, with up to 24 Regions of Interest (ROI) per sample to be mutually agreed upon, to be used with the GeoMx® Whole Transcriptome Atlas (WTA) and Illumina NGS appropriate reagents for use with the Illumina NextSeq™ 2000 Sequencing System.
The samples will run through NanoString’s GeoMx® Digital Spatial Profiling Technology Access Program inclusive of the Illumina NGS readout. An assay report, including raw data and processed results, will be provided to the winner.
By submitting a grant application, each applicant agrees that NanoString may use his or her name, abstract title, for marketing purposes.
All grant applicants agree that NanoString may process the personal data he or she provides as part of application, including sharing such data with NanoString’s partners, collaborators and other third parties who are obligated to keep the data confidential, and in accordance with NanoString’s privacy policies available at www.nanostring.com/privacy.
NanoString will not share with Illumina any information on the applicant’s submissions or the submissions themselves, or data, samples or results associated with the submissions. All submissions, samples and data must be sent directly to NanoString. Illumina will not be involved in the selection process for the grant winner and will be only providing the necessary sequencing reagent kit to NanoString for it to perform the sequencing activity upon award of the grant, subject to an agreement between Illumina and NanoString.
The grant award winner may be required to sign and return an affidavit of eligibility, release of liability, a publicity release, and other appropriate legal documentation reasonably requested by NanoString. No substitution or transfer of the awarded prize is allowed except as permitted by NanoString. The award winner is responsible for any local tax liability (city, state, or federal) occurred by winning and accepting the award. If, for any reason, the grant program may not run as planned for any causes beyond the reasonable control of NanoString, then NanoString reserves the right in its sole discretion to cancel, terminate, modify or suspend the grant program. These terms and conditions and any action related to this grant program will be governed by the laws of the State of Washington without regard to or application of its conflict of law provisions or your state or country of residence. All claims, legal proceedings or litigation arising in connection with these terms and conditions and this grant program will be brought solely in the federal or state courts located in Seattle, Washington, and all applicants consent to the jurisdiction of and venue in such courts and waive any objection as to inconvenient forum. By participating in this grant program, each applicant unconditionally accepts and agrees to comply with and abide by these terms and conditions.